



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/36, 15/62, 15/70, 1/21, C07K</b> <b>16/08, A61K 38/16, 39/29, 48/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/15671</b> <b>(43) International Publication Date:</b> 1 April 1999 (01.04.99)
<b>(21) International Application Number:</b> PCT/GB98/02852 <b>(22) International Filing Date:</b> 21 September 1998 (21.09.98) <b>(30) Priority Data:</b> 9720033.1 19 September 1997 (19.09.97) GB <b>(71) Applicant (for all designated States except US):</b> MEDEVA EUROPE LIMITED [GB/GB]; 10 St. James's Street, London SW1A 1EF (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> CHATFIELD, Steven, Neville [GB/GB]; Medeva plc, 10 St. James's Street, London SW1A 1EF (GB). <b>(74) Agent:</b> WOODS, Geoffrey, Corlett; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> HEPATITIS B VIRUS POLYPEPTIDES  <b>(57) Abstract</b> <p>The present invention provides a polypeptide comprising tetanus toxin fragment C, or a fragment thereof, fused to the pre-S1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the pre-S2 region of HBV or a fragment thereof. It also provides vaccine compositions comprising the polypeptide of the invention.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

## **HEPATITIS B VIRUS POLYPEPTIDES**

### **Field of the invention**

This invention relates to fusion polypeptides derived from the surface antigen  
5 of hepatitis B virus and their use in vaccine compositions.

### **Background to the invention**

Hepatitis B infection and consequential diseases which include chronic liver  
disease, cirrhosis and hepatocellular carcinoma are a major health problem  
10 throughout the world. Systematic vaccination of individuals at risk of exposure to  
the virus has been the main method of controlling infection. The first hepatitis B  
virus (HBV) vaccine was manufactured by the purification and inactivation of HBV  
surface antigen (HBsAg) obtained from the plasma of chronic carriers. This was  
soon followed by the production of HBsAg using recombinant DNA techniques.  
15 However, a significant proportion of individuals do not mount antibody responses to  
the HBsAg present in vaccine preparations and it is considered that these individuals  
remain susceptible to infection with HBV.

### **Summary of the Invention**

20 The present invention provides a polypeptide comprising tetanus toxin  
fragment C, or a fragment thereof, fused to the pre-S1 region of hepatitis B virus  
(HBV), or a fragment thereof, and/or the pre-S2 region of HBV or a fragment  
thereof.

Preferably said fragment of the pre-S1 region and pre-S2 region comprises at  
25 least 5 amino acids, more preferably at least 6 amino acids, most preferably 10, 15 or  
20 amino acids.

The tetanus toxin fragment C or fragment thereof may be fused to the pre-S1  
region, or fragment thereof, of hepatitis B virus (HBV) or the pre-S2 region of HBV,  
or fragment thereof, via a "hinge" linker region. Similarly, where both a fragment of  
30 the pre-S1 region and a fragment of the pre-S2 region are present, they may be joined  
together by a "hinge" linker region.

-2-

The present invention further provides a polynucleotide encoding a polypeptide of the invention

The present invention also provides vectors comprising a polynucleotide encoding a polypeptide of the invention operably linked to a regulatory sequence. Preferably the regulatory sequence allows expression of the polypeptide in a host cell. Typically the host cell is a bacterium, which may be attenuated or a cell of an animal, more preferably a mammal, including primates and humans.

The polypeptides, polynucleotides and vectors and host cells of the present invention may be used in the prevention or treatment of hepatitis B viral infections. Thus, in a further aspect, the present invention provides a vaccine composition comprising a polypeptide, polynucleotide or vector of the invention together with a pharmaceutically acceptable carrier or diluent. The vaccine composition may comprise attenuated bacterium transformed with a polynucleotide of the invention. It may be preferred to use the polypeptides of the invention in combination with the active constituents of other HBV vaccine compositions to increase their effectiveness. Thus the vaccine composition of the invention preferably further comprises, for example, the polypeptide components of the HBV vaccine described in WO88/10301 (i.e. the S, S+pre-S2 and S+amino acids 20 to 47 of pre-S1 antigenic components of both subtypes *adw* and *ayw*).

The present invention also provides a method of treating or preventing HBV infection in a human or animal which comprises administering to the human or animal an effective amount of a polypeptide, polynucleotide or vector of the invention.

The polypeptides of the invention may also be used to induce antibody responses in animals for the purpose of producing antibodies that recognise epitopes within the pre-S1 and/or pre-S2 regions of HBV. Thus the present invention provides a method for producing antibodies which recognise epitopes within the pre-S1 and/or pre-S2 regions of HBV which method comprises administering a polypeptide, polynucleotide or vector of the invention to a mammal. The resulting antibodies may be polyclonal antibodies or monoclonal antibodies, or fragments thereof. These antibodies may be used in a method of treating HBV infection in a

-3-

human or animal.

In addition to the potential therapeutic uses of the polypeptides, polynucleotides, vectors and antibodies of the invention, they may also be used as tools to determine, for example, antigenic determinants within the pre-S1 and/or pre-S2 regions of the HBV surface antigen (HBsAg). Both regions are believed to play important roles in augmenting anti-HBsAg responses which prevent attachment of the virus to hepatocytes and elicit antibodies which are effective in viral clearance, stimulating cellular immune responses and circumventing genetic non-responsiveness to the S region alone.

#### Detailed Description of the Invention

##### A. Polypeptides

The polypeptides of the invention comprise tetanus toxin fragment C or an epitope containing fragment thereof fused to a fragment of the pre-S1 region of hepatitis B virus (HBV) and/or a fragment of the pre-S2 region of HBV.

The structural gene for tetanus toxin has been cloned and sequenced (Fairweather et al. (1986), *J. Bacteriol.*, 165, p21-27). Fragment C is a 50 kDa polypeptide generated by papain cleavage and comprises or substantially corresponds to the 451 amino acids at the C-terminus. Fragments of tetanus toxin fragment C that contain epitopes may also be used in the polypeptides of the invention. These fragments will comprise at least 5 or 6 amino acids, preferably at least 10 amino acids, more preferably at least 15, 20, 50 or 100 amino acids. Particularly preferred fragments include from about amino acids 80 to 180, which is a good B-cell epitope, and from about amino acids 83 to 103 and 409 to 420 which are good T-cell epitopes (numbering assumes that amino acid 1 of fragment C is amino acid 864 of the complete tetanus toxin).

Preferably the fragment of the pre-S1 region and pre-S2 region comprises at least 5 amino acids, more preferably at least 6 amino acids, most preferably 10, 15 or 20 amino acids. The fragment may include, for example, amino acids 1 to 19, 20 to 39, 40 to 59, 60 to 79, 80 to 99 or 100 to 119 of pre-S1, or 1 to 19, 20 to 39 or 40 to 55 of pre-S2. Suitable fragments which may be used in the polypeptides of the

-4-

invention are described in the Examples. Particularly preferred fragments include amino acids 20 or 21 to 47 of pre-S1 (the hepatocyte binding site) and amino acids 1 to 26 and 14 to 32 of pre-S2.

Further, the amino acid sequence of tetanus toxin fragment C and the fragments of the pre-S1 and pre-S2 regions can be modified to provide polypeptides of the invention. For example, this may be carried out to enhance the immunogenicity of the polypeptides of the invention. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified polypeptide retains epitopes.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

The tetanus toxin fragment C may be fused to the fragment of the pre-S1 region of hepatitis B virus (HBV) or the fragment of the pre-S2 region of HBV via a "hinge" linker region. Similarly, where both a fragment of the pre-S1 region and a fragment of the pre-S2 region are present, they may be joined together by a "hinge" linker region.

-5-

The "hinge" linker region is a region designed to promote the independent folding of both the tetanus toxin fragment C, fragment of the pre-S1 region and the fragment of the pre-S2 region by providing both spatial and temporal separation between the domains.

5        The hinge region typically is a sequence encoding a high proportion of proline and/or glycine amino acids. The hinge region may be composed entirely of proline and/or glycine amino acids. The hinge region may comprise one or more glycine-proline dipeptide units. In the alternative the hinge region may comprise the carboxy terminal of tetanus toxin fragment C.

10       The hinge region may, for example, contain up to about fifteen amino acids, for example at least 4 and preferably from 6 to 14 amino acids, the number of amino acids being such as to impart flexibility between the different polypeptide domains:

In one embodiment, the hinge region can correspond substantially to the hinge domain of an antibody immunoglobulin. The hinge regions of IgG antibodies  
15 in particular are rich in prolines (T.E. Michaelson *et al.* (1977) J. Biol. Chem. **252**, p883-9), which are thought to provide a flexible joint between the antigen binding and tail domains.

Other amino acids may be substituted for glycine, particularly those without bulky side-chains, such as alanine, serine, asparagine and threonine.

20       In one preferred embodiment, the hinge region is a chain of four or more amino acids defining the sequence:

-[X]<sup>p</sup>-Pro-[Y]<sup>q</sup>-Pro-[Z]<sup>r</sup>-

wherein Pro is proline, X and Y are each glycine, or an amino acid having a non-bulky side chain; Z is any amino acid; p is a positive integer; q is a positive integer of  
25 from one to ten; and r is zero or a positive integer greater than zero.

#### B. Polynucleotides and vectors.

Polynucleotides of the invention comprise nucleic acid sequences encoding the polypeptides of the invention. Polynucleotides of the invention may comprise  
30 DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to

-6-

oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention.

Preferred polynucleotides of the invention also include polynucleotide encoding any of the polypeptides of the invention described above. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code.

Polynucleotides of the invention comprise can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide of the invention in a vector is operably linked to a regulatory sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

Such vectors may be transformed or transfected into a suitable host cell as described above to provide for expression of a polypeptide of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding



-7-

sequence encoding the polypeptides. The expressed polypeptides may be recovered *in vitro*. Host cells transformed to provide stable expression of the polypeptides may also be used *in vivo*. For example, a host cell such as an attenuated bacterium transformed to express a polypeptide of the invention may be used as a vaccine. The  
5 attenuated bacterium may be selected from *Salmonella*, *Bordetella*, *Vibrio*, *Haemophilus*, *Neisseria* and *Yersinia*. More preferably the attenuated bacterium is an enterobacteria such as *E.coli* or *Salmonella*, such as, *S.typhis*, *S.typhimurium* or *S.enteritidis*.

The vectors may be for example, plasmid or virus vectors provided with an  
10 origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used *in vitro*, for example for the production of RNA or used to  
15 transfect or transform a host cell. The vector may also be adapted to be used *in vivo*, for example in a method of gene therapy.

Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. For example, prokaryotic promoters may be used, in particular those suitable for use in *E.*  
20 *coli* strains (such as *E. coli* HB101). In a particularly preferred embodiment of the invention, a promoter whose activity is induced in response to a change in the surrounding environment, such as anaerobic conditions is used. Preferably an *htrA* or *nirB* promoter may be used. These promoters may be used in particular to express the polypeptides in attenuated bacterium for example for use as a vaccine. When  
25 expression of the polypeptides of the invention is carried out in mammalian cells, either *in vitro* or *in vivo*, mammalian promoters may be used. Tissues-specific promoters, for example hepatocyte cell-specific promoters, may also be used. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the promoter of rous sarcoma virus (RSV) LTR  
30 promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter,

-8-

herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art.

C. Administration

5           The polypeptides of the invention may be administered by direct injection. Preferably the polypeptides are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, intranasal, 10           subcutaneous, intraocular or transdermal administration. Typically, each polypeptide is administered at a dose of from 0.01 to 30 µg/kg body weight, preferably from 0.1 to 10 µg/kg, more preferably from 0.1 to 1 µg/kg body weight. It is also possible to use antibodies prepared using the polypeptides of the invention, as described below, in treating or preventing HBV infection. Neutralising antibodies, or fragments 15           thereof which retain specificity for HBV antigens, can be administered in a similar manner to the polypeptides of the invention.

          The polynucleotides of the invention may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. When the expression cassette is administered as a naked 20           nucleic acid, the amount of nucleic acid administered is typically in the range of from 1 µg to 10 mg, preferably from 100 µg to 1 mg.

          Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example 25           calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam™ and transfectam™). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

          Preferably the polynucleotide or vector of the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical 30           composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for

-9-

parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

#### D. Preparation of Vaccines

Vaccines may be prepared from one or more polypeptides of the invention. They may also include one or more immunogenic HBV polypeptides, for example immunogenic HBV polypeptides known in the art. Thus a vaccine of the invention may comprise one or more polypeptides of the invention and optionally, one or more polypeptides selected from HBV S, pre-S1, pre-S2 polypeptides and immunogenic fragments thereof.

The polypeptides of the invention may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.

The preparation of vaccines which contain an immunogenic polypeptide(s) as active ingredient(s), is known to one skilled in the art. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes.

The vaccine may comprise an attenuated bacterium capable of expressing the polypeptide of the invention.

The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable

-10-

excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.

In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing an HBV antigenic sequence resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and intranasal formulations. Oral formulations may be provided, in particular for administration of attenuated bacterium. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1% to 2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%.

The vaccine, for example, comprising an attenuated bacterium is advantageously presented in lyophilised form, for example in capsular form, for oral

-11-

administration to a patient. Such capsules, tablets and pills for oral administration to a patient may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose. These capsules may be used as such, or  
5 alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in buffer at a suitable pH to ensure the viability of the organisms. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine.

10

#### E. Dosage and Administration of Vaccines

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered, which is generally in the range of 5  $\mu$ g to  
15 250  $\mu$ g of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgement of the practitioner and may be peculiar to each subject.

The vaccine may be given in a single dose schedule, or preferably in a  
20 multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1 to 4 months for a second dose, and if needed, a subsequent dose(s) after several months. The dosage regimen will also, at least in part, be determined by  
25 the need of the individual and be dependent upon the judgement of the practitioner.

In addition, the vaccine containing the immunogenic HBV antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins.

-12-

F. Preparation of antibodies against the polypeptides of the invention

The immunogenic polypeptides prepared as described above can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing an HBV epitope(s). Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an HBV epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.

Monoclonal antibodies directed against HBV epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. Panels of monoclonal antibodies produced against HBV epitopes can be screened for various properties; i.e., for isotype and epitope affinity.

Antibodies, both monoclonal and polyclonal, which are directed against HBV epitopes are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies. Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired.

Techniques for raising anti-idiotypic antibodies are known in the art. These anti-idiotypic antibodies may also be useful for treatment of HBV, as well as for an elucidation of the immunogenic regions of HBV antigens.

It is also possible to use fragments of the antibodies described above, for example, Fab fragments.

-13-

### G. Immunoassays

Both the polypeptides of the invention, and antibodies produced using the polypeptides of the inventions may be used in immunoassay methods, for example which react immunologically with serum containing HBV antibodies, for example to  
5 detect presence of HBV antibodies, or the presence of viral antigens, in biological samples, including for example, blood or serum samples. In particular, the polypeptides and antibodies of the invention may be used to map highly immunogenic regions within the pre-S1 and pre-S2 regions of HBsAg. Design of the immunoassays is subject to a great deal of variation, and a variety of these  
10 immunoassays are known in the art. For example, the immunoassay may utilise one viral antigen, for example, a polypeptide of the invention; or alternatively, the immunoassay may use a combination of viral antigens including a polypeptide of the invention. It may also use, for example, an antibody obtained using a method of the invention or a combination of these antibodies directed towards one viral antigen or  
15 several viral antigens. Protocols may be based, for example, upon competition, or direct reaction, or sandwich type assays. The immunoassay protocols used may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labelled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify  
20 the signals from the probe are also known; examples of which are assays which utilise biotin and avidin, and enzyme-labelled and mediated immunoassays, such as ELISA assays.

The invention will be described with reference to the following Examples  
25 which are intended to be illustrative only and not limiting. The Examples refer to the Figures. Referring to the Figures in more details:

### Description of the Figures

30 Figure 1 depicts the cloning scheme for plasmid pTECH3

-14-

## Figure 2

- a) Total Immunoglobulin response, anti-Fragment C, 14 days post prime dose with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response (▲).
- 5 b) Total Immunoglobulin response, anti-Fragment C, 7 days post boost dose with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response (▲).

## Figure 2

- 10 a) Total immunoglobulin response, anti-S1 (aa61-81 peptide), 14 days post prime dose with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response (▲).
- b) Total immunoglobulin response, anti-S1 (aa61-81 peptide), 7 days post boost with (■) and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse
- 15 serum (non-immunised) response (▲).

## Figure 4

- a) Total immunoglobulin response, anti-S1 (aa12-24 peptide), 14 days post prime dose with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified
- 20 fusion proteins. Normal mouse serum (non-immunised) response (▲).
- b) Total immunoglobulin response, anti-S1 (aa12-24 peptide), 7 days post boost with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response (▲).

## 25 Figure 5

- a) Total immunoglobulin response, anti-S1 (aa21-47 peptide, present in S-pre-S1 particles), 14 days post prime dose with (■) Fragment C-SΔS1/S2 and (●) Fragment C-BΔS1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response (▲).
- 30 b) Total immunoglobulin response, anti-S1 (aa21-47 peptide, present in S-pre-S1 particles), 7 days post boost dose with (■) Fragment C-SΔS1/S2 and (●)



-15-

Fragment C-B $\Delta$ S1/S2 purified fusion proteins. Normal mouse serum (non-immunised) response ( $\blacktriangle$ ).

### EXAMPLES

5

#### Example 1 – Preparation of expression constructs

Plasmid pTECH-3, the basic expression vector used in these examples, was prepared as shown in Figure 1 from pTECH-2 and pTEThtA-1 as described in our earlier application PCT/GB95/00196. pTECH-3 comprises a sequence encoding the tetanus toxin fragment C and containing a hinge region, operably linked to the *htrA* promoter.

10

The constructs described in the table below were constructed as follows:

15 Table 1

Construct	Hepatitis B sequence
pTECH3/S1	pre S1 <sub>ayw</sub> 21-47aa
pTECH3/S2	pre S2 <sub>ayw</sub> 1-55aa
pTECH3/S1/S2	pre S1 <sub>ayw</sub> 21-47/preS2 <sub>ayw</sub> 1-55aa
20 pTECH3/SB	S <sub>ayw</sub> 120-147aa
pTECH3/S $\Delta$ S1/S2	pre S1 <sub>adw</sub> 21-119/S2 <sub>adw</sub> 1-55aa
pTECH3/B $\Delta$ S1/S2	pre S1 <sub>adw</sub> 42-119/S2 <sub>adw</sub> 1-55aa
pTECH3/WS1/S2	pre S1 <sub>adw</sub> 1-119/S2 <sub>adw</sub> 1-55aa

20

25 Plasmid pMBdS1RN/44 (containing the *ayw* hepatitis B pre-S1(20-47)/S gene) was used as template for constructing pTECH3/S1, pTECH3/SB and pTECH3/S1/S2. pMByS2/8 (containing the *ayw* hepatitis B pre-S2(1-55)/S gene) was used as the template for pTECH3/S2 and pTECH3/S1/S2 and pRIT12793 (containing the entire *adw* hepatitis B pre-S1/S2 gene in pBR322) was used for

30 pTECH3/S $\Delta$ S1/S2, pTECH3/B $\Delta$ S1/S2, and pTECH3/WS1/S2.

-16-

The following pairs of primers were used to PCR clone, using standard conditions, the hepatitis B pre-S1/S2 sequences for insertion into pTECH3:

	Primer	Sequence
5	MGR178(SB)	ACTCTAGATGCAAAACCTGC
	MGR179(SB)	TAACTAGTAATACAGGTGCA
	MGR104(S1 and S1/S2)	ATGTCTAGAAATCCTCTGGGATTC
	MGR238(S2 and S1/S2)	AAGCTTATGCAGTGGAATTCCAGA
	MGR105(S1)	CGAACTAGTGTGGGATTGAAGTC
10	MGR106(S2)	AGGGTCACTAGTCCTCGAGAAGAT
	MGR252(S $\Delta$ S1/S2)	TCTGTTGCTAGCCCTCTGGGATTC
	MGR254(B $\Delta$ S1/S2)	TCAAACGCTAGCGATTGGGACTTC
	MGR243(S $\Delta$ and B $\Delta$ S1/S2)	TTGCTAGCGTTCAGCGCAGGGTCC
	MGR250(W31/S2)	CCCGCTAGCATGGGAGGTTGGTCA

15

Each PCR fragment was digested with restriction enzymes, gel purified and ligated with a 3.76 kbp pTECH3 fragment. The first four constructs were made by digesting the pTECH3 plasmid with XbaI/SpeI/CIAP to produce the 3.76 kbp fragment. The appropriate HBV PCR fragment which had been pre-cut with NheI was then ligated to the 3.76 kbp fragment. The last two constructs were made by digesting pTECH3 plasmid with XbaI/CIAP to produce the 3.76 kbp fragment which was then ligated with the appropriate HBV PCR product which had been pre-cut with NheI.

20

## 25 Example 2 – Expression of polypeptides and Western Blotting

Plasmids were transformed into *E. coli* strain HB101 using standard techniques. Expression of fusion polypeptides was induced by heat stress at 37°C. Expression was tested by western blotting *E. coli* cellular extracts with anti-tetanus toxin fragment C antibody and specific antibodies for each insert sequence (see Table

30

2).

-17-

Example 3 – Production of polyclonal antibodies against polypeptide constructs

The fusion polypeptides produced in Example 2 from plasmids pTECH3/sΔS1/S2 and pTECH3/BΔS1/S2 were purified from *E. coli* cellular extracts by affinity chromatography using anti-tetanus toxin fragment C as the ligand immobilised to the sepharose 4B column. Purified proteins were prepared for injection and administered to mice (B10, female, 6-8 weeks old) using standard techniques and as detailed below.

Schedule

10

Group 1

Immunise mice (prime dose) intra-peritoneal I/P with 5 µg purified Frag C-SΔS1/S2 fusion protein.

Sample bleed 14 days post prime dose.

Immunise mice (boost dose) I/P with 5 µg purified Frag C-SΔS1/S2 fusion protein, 21 days post prime dose

Bleed-out mice 7 days post boost dose.

15

Group 2

Immunise mice (prime dose) intra-peritoneal I/P with 5 µg purified Frag C-BΔS1/S2 fusion protein.

Sample bleed 14 days post prime dose.

Immunise mice (boost dose) I/P with 5 µg purified Frag C-BΔS1/S2 fusion protein, 21 days post prime dose

Bleed-out mice 7 days post boost dose.

20

25

Total antibody responses were determined by ELISA against purified fragment C, pre-S1 (aa61-81), pre-S2 (aa12-24) peptides and pre-S1 (aa21-47) contained within S-S1 particles. Responses are illustrated in Figures 2, 3, 4 and 5 respectively.

30

In summary, responses were detected to both pre-S1 and pre-S2 components of the fusion proteins, and the fragment C carrier protein.

Table 2 - Western Blots

Construct	Hepatitis B sequence	Western blot				
		Frag C <sup>(a)</sup>	S1 (20-47) <sup>(b)</sup>	S1 (61-81) <sup>(c)</sup>	S2 <sup>(d)</sup>	S <sup>(e)</sup>
pTECH3/S1	pre S1 <sub>ayw</sub> 21-47aa	+	+	ND	ND	ND
pTECH3/S2	pre S2 <sub>ayw</sub> 1-55aa	+	ND	ND	+	ND
pTECH3/S1/S2	pre S1 <sub>ayw</sub> 21-47/preS2 <sub>ayw</sub> 1-55aa	+	ND	ND	+	ND
pTECH3/SB	S <sub>ayw</sub> 120-147aa	+	+	ND	ND	+
pTECH3/SΔS1/S2	pre S1 <sub>adw</sub> 21-119/S2 <sub>adw</sub> 1-55aa	+	+	+	+	ND
pTECH3/BΔS1/S2	pre S1 <sub>adw</sub> 42-119/S2 <sub>adw</sub> 1-55aa	+	+	+	+	ND
pTECH3/WS1/S2	pre S1 <sub>adw</sub> 1-119/S2 <sub>adw</sub> 1-55aa	+	+	ND	+	ND

(a) Polyclonal rabbit anti-FragC sera AB96-05 14/3/97 1:100

(b) Monoclonal mouse anti-S1 (20-47) 18/7/97 (from Speke) 1:1000.

(c) Polyclonal rabbit anti-S1 (60-80) RA2138 Rabbit 9393 27/7/87 1:400.

(d) Monoclonal mouse anti-S2 1-901 cell supernatant Harv. 20/11/97. Fre 26/11/97 1:10.

(e) Polyclonal mouse (SWR/J) anti-HB147 (VRU, Imperial College) 1:50.


ND = not done

CLAIMS

1. A polypeptide comprising tetanus toxin fragment C, or a fragment thereof, fused to the pre-S1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the pre-S2 region of HBV or a fragment thereof.
- 5 2. A polynucleotide encoding a polypeptide according to claim 1
3. A vector comprising a polynucleotide according to claim 2 operably linked to a regulatory sequence.
4. A vector according to claim 2 wherein said regulatory sequence comprises an *htrA* promoter sequence.
- 10 5. A host cell comprising a vector according to claim 3 or 4.
6. A host cell according to claim 5 which is a bacterium.
7. A vaccine composition comprising a polypeptide according to claim 1, a polynucleotide according to claim 2 or a vector according to claim 3 or 4 together with a pharmaceutically acceptable carrier to diluent.
- 15 8. A method of treating or preventing HBV infection in a human or animal which comprises administering to the human or animal an effective amount of a polypeptide according to claim 1, a polynucleotide according to claim 2 or a vector according to claim 3 or 4.
9. A method for producing antibodies which recognise epitopes within the pre-S1 and/or pre-S2 regions of HBV which method comprises administering a polypeptide according to claim 1, a polynucleotide according to claim 2 or a vector according to claim 3 or 4 to a mammal.
- 20 10. An antibody produced by the method of claim 9.
11. A method of treating HBV infection in a human or animal which comprises administering to a human or animal an effective amount of an antibody according to claim 10.
- 25

1/5



Fig.1.



SUBSTITUTE SHEET (RULE 26)

2/5



Fig.2.



SUBSTITUTE SHEET (RULE 26)

3/5

Fig.3.




SUBSTITUTE SHEET (RULE 26)



4/5


Fig.4.



SUBSTITUTE SHEET (RULE 26)

5/5

Fig.5.



SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 98/02852

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/36 C12N15/62 C12N15/70 C12N1/21 C07K16/08  
A61K38/16 A61K39/29 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 389 983 A (ABBOTT LAB) 3 October 1990 see the whole document ---	10,11
Y	WO 94 03615 A (MEDEVA HOLDINGS BV ;KHAN MOHAMMED ANJAM (GB); HORMAECHE CARLOS EST) 17 February 1994 see esp p. 3-16; examples ---	1-11
Y	SHI C -H ET AL: "Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein" VACCINE, vol. 13, no. 10, July 1995, page 933-937 XP004057512 see the whole document --- -/-	1-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 January 1999

Date of mailing of the international search report

04/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

# INTERNATIONAL SEARCH REPORT

Int      tional Application No  
PCT/GB 98/02852

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 20665 A (MEDEVA HOLDINGS BV ;KHAN MOHAMMED ANJAM (GB); CHATFIELD STEVEN NEV) 3 August 1995 cited in the application see the whole document ---	4-11
A	WO 95 04151 A (MEDEVA HOLDINGS BV ;KHAN MOHAMMED ANJAM (GB); HORMAECHE CARLOS EST) 9 February 1995 see the whole document ---	1-11
A	KHAN C. ET AL.: "Construction, expression, and immunogenecity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella" PNAS,U.S.A., vol. 91, no. 23, 1994, pages 11261-11265, XP002090995 see discussion ---	1-11
A	WO 94 01132 A (MERCK & CO INC ;KNISKERN PETER J (US); HAGOPIAN ARPI (US); BURKE P) 20 January 1994 see the whole document ---	1-11
A	WO 88 10300 A (MEDICO LABS AG) 29 December 1988 cited in the application see the whole document -----	1-11

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/02852

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 8, 11, and claim 9 partially,  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 98/02852

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0389983	A	03-10-1990	AU 628156 B	10-09-1992
			AU 5223990 A	08-11-1990
			CA 2013517 A	30-09-1990
			JP 3027297 A	05-02-1991
WO 9403615	A	17-02-1994	AT 174628 T	15-01-1999
			AU 4719393 A	03-03-1994
			CA 2141427 A	17-02-1994
			EP 0652962 A	17-05-1995
			EP 0863211 A	09-09-1998
			FI 950396 A	30-01-1995
			JP 8503602 T	23-04-1996
			NO 950348 A	28-03-1995
WO 9520665	A	03-08-1995	AU 1541595 A	15-08-1995
			BR 9506666 A	09-09-1997
			CZ 9602182 A	16-10-1996
			EP 0742829 A	20-11-1996
			FI 963016 A	25-09-1996
			HU 75734 A	28-05-1997
			JP 9508276 T	26-08-1997
			NZ 278930 A	28-07-1998
			PL 315670 A	25-11-1996
			SK 99696 A	08-01-1997
WO 9504151	A	09-02-1995	AU 4719393 A	03-03-1994
			AU 7235794 A	28-02-1995
			CA 2168459 A	09-02-1995
			CZ 9600241 A	12-06-1996
			EP 0652962 A	17-05-1995
			EP 0712442 A	22-05-1996
			FI 950396 A	30-01-1995
			JP 8503602 T	23-04-1996
			JP 9500540 T	21-01-1997
			NO 950348 A	28-03-1995
			PL 313979 A	05-08-1996
			GB 2295394 A, B	29-05-1996
			HU 74495 A	28-01-1997
			SK 9996 A	04-09-1996
WO 9401132	A	20-01-1994	AU 4659993 A	31-01-1994
WO 8810300	A	29-12-1988	AU 1985588 A	19-01-1989
			AU 1995888 A	19-01-1989
			WO 8810301 A	29-12-1988
			EP 0299242 A	18-01-1989
			EP 0304578 A	01-03-1989
			EP 0300213 A	25-01-1989
			JP 2501186 T	26-04-1990
			JP 2501187 T	26-04-1990
			JP 2758184 B	28-05-1998
			KR 9707153 B	03-05-1997